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ABSTRACT
Although the antibacterial property of nitric oxide (NO) has been well documented in gram po-
sitive and gram negative bacteria cultures, its cytotoxic effects are not completely clear. To limit 
potential in vivo cytotoxicity, our group recently investigated the effects of a range of NO fluxes 
on S. epidermidis and S. aureus to determine a minimum effective NO level. In this study, we 
report the antibacterial function of this minimum NO level also on gram negative Pseudomo-
nas aeruginosa as well as its cytocompatibility effects on lung and kidney cells. Standardized 
bacterial cultures were treated with NO releasing PDMS substrates followed by plating, 24hr 
incubation, and colony analyses. Cytocompatibility or cell viability was conducted on WI-38 
human lung fibroblasts and HEK-293 human embryonic kidney cells after their exposure to NO 
in vitro. NO flux of 21.18 ± 5.31 × 10−10 mol/ min/ cm2 significantly reduced P. aeruginosa 
growth compared to controls and PDMS-treated samples (p value < 0.0001). No significant dif-
ferences was seen between control and cells treated at this flux (total moles delivered in 24hrs 
= 0.76 ± 0.18), but a significant reduction was observed at 45.1 ± 2.55 ×10−10 mol/ min/ cm2 
(total moles delivered = 1.6 ± 0.09). The results suggest that at the lower NO flux level pseudo-
monas aeruginosa growth is significantly inhibited while maintaining cell viability.
Keywords:  functional biomaterials, bactericidal surfaces, bacterial infection,communicable 
medical materials, nitric oxide
INTRODUCTION
Nitric oxide is a multifaceted biological molecule with many physiological functions including 
acting as an antibacterial agent1-4 and a promoter of cell proliferation.5, 6 However, it can be 
harmful to cells when delivered at levels incompatible with normal cellular function.7 A crucial 
objective pertaining to functional materials formulated to deliver NO is to ensure inconsequen-
tial cell toxicity effects if any occurs at all. It is therefore critical that biomedical applications 
that incorporate these properties for developing functional and bioinspired biomaterials aim for 
the compatible concentrations.
At high and bactericidal concentrations, NO exerts bactericidal effects through many mecha-
nisms via NO itself or its byproducts.8, 9-11 The interaction of NO with superoxide (O2-) within 
or outside microbial cell yield reactive nitrogen species (RNOS), that are known to induce 
nitrosative and oxidative stresses to disrupt microbe’s membranes through lipid peroxidation9 
as well as induce DNA damage. Moreover, NO can nitrosate cycteine and tyrosine leading to 
dysfunction of many key bacterial enzymes, proteins, and cell membrane adhesion proteins that 
mediate cell-substrate attachment.5 Accordingly the exploitation of these properties have been 
pursued using several materials to deliver various levels of NO to bacteria cultures. While the 
research outcomes do show antibacterial activity, the exact therapeutic concentration of NO 
remain unclear. Nonetheless, such exact or range of bactericidal concentration(s) must also be 
cytocompatible to ensure selective elimination of bacteria after they are released by functional 
materials which may serve as surfaces of blood/tissue communicable devices.
Simultaneously, the interaction of high NO and its byproducts with cells, although bactericidal, 
can be detrimental to cells due to incompatibility and lead to many biological dysfunctions.12-17 
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Many cellular and tissue functions including DNA alterations 
and subsequent cell anti- proliferation activity18, 19 can be impai-
red.
Therefore, studies that have investigated striking a balance 
between effective bactericidal activity and cytocompatibility 
using an optimal dose(s) of NO are being pursued for more con-
clusive data. Data from experiments conducted in vitro under 
conditions of NO gas flow20-24 and in vivo using material-assisted 
NO delivery report the effects of different ranges of NO con-
centration on different compatibility outcomes.25 In this study 
we investigate the effects of a wide range of NO fluxes (surface 
area and time normalized NO release), from low, protective, and 
proliferative fluxes to high levels, on cytocompatibility of lung 
and kidney cells in vitro. This evaluation method is important for 
the effective application of NO releasing polymers as coatings 
on implantable medical devices.
MATERIALS AND METHODS
Preparation of NO donor compounds for modification of PDMS 
substrates 
      
Conjugation of NO to secondary amine linear polymers (dimeth-
ylhexanediamine or DMHD) to form diazeniumdiolated DMHD 
or DMHD/N2O2, which was then incorporated into polydimeth-
ylsiloxane (PDMS) along with poly (lactic-co-glycolic acid) or 
PGLA is shown in (Scheme 1).26, 27 Hydrolysis of PLGA aids the 
catalysis of NO from preformed NO donor compounds embed-
ded within the PDMS polymer.
As previously described,28 synthesis of NO releasing PDMS 
substrates, as model materials for biological testing, was achie-
ved via polymerization of a two-part silicone rubber (R21-2615, 
NuSil, CA). A 1:1 ratio of resin A (PDMS oligomer) and resin 
B (PDMS oligomer with platinum initiator) mixed in organic 
solvent (Mineral Spirit, Sigma-Aldrich, MO) was cured over-
night at room temperature into 1mm thick base layers. 100 µl 
mixtures of THF solvent containing PDMS resin, 15 wt% of 
DMHD/N2O2, and 15 or 25 wt% of PLGA (Evonik, NJ) were 
Scheme 1: Reaction of nitric oxide (NO) with linear dimethylhexanediamine to form diaze-
niumdiolate, and the subsequent release of the NO stimulated by hydrolysis of polylactide-
glycolide acid and physiological conditions.
then casted atop a PDMS-only base layer, cured for 24hrs and 
followed by top casting 100 µl of PDMS solution and curing for 
another 24hrs.
Characterization of nitric oxide (NO) release
Real time NO release from modified PDMS and controls sam-
ples were quantified by chemiluminescence method using a 
GE 280i nitric oxide analyzer ((NOA), GE Instruments, CO). 
To measure NO release, samples were immersed in 10 ml PBS 
(pH 7.4) at 37°C inside the NOA reaction vessel. Nitrogen was 
used as a carrier gas to transport NO from the reaction vessel 
to the chemiluminescence detection chamber and NO flux from 
modified PDMS samples was calculated as the quotient of the 
products of NO concentration detected by NOA (ppb or ppm) 
and NOA calibration factor (mol/ppb*sec), and sample surface 
area (cm2) and duration NO detection (sec or min).
In vitro antibacterial test
Pseudomonas aeruginosa derived from ATCC 9027 was pur-
chased from Microbiologics, and was cultured using Nutrient 
agar (NA) plates at 35°C. Overnight Bacterial cultures solutions 
were adjusted to make a final cell concentration at ~108 CFU/
ml. Each NO releasing or control PDMS substrates was placed 
into a sterile 15-mL tube with 2 mL of the bacterial culture. The 
tubes were incubated at 37°C for 24 h while shaking (140 rpm). 
After incubation, the substrates were removed aseptically and 
bacterial culture was diluted in PBS buffer. 1 µL of each dilu-
tion was streaked onto NA plates for viable bacterial counting. 
The NCBI, Image J software was used for colony count. PDMS 
substrates and levofloxacin, 6mm paper disks saturated with 5 
µg of levofloxacin (Hardy Diagnostics Inc), were used as ad-
ditional controls.
   
In vitro cytocompatibility test
       
To determine the effect of the application of NO releasing PDMS 
on healthy cells, two human cell lines were exposed to NO re-
lease from PDMS and cell viabilities were quantified.
Cell culture
WI-38 human lung fibroblasts and HEK-293 human embryonic 
kidney cell lines were purchased from ATCC. WI-38 cells were 
maintained in MEM media (Sigma-Aldrich, Saint Louis MO) 
supplemented with 10% FBS (Gemini Biosciences, Denver CO), 
1% Sodium Pyruvate, 1% l- glutamine, and 1% Penicillin/Strep-
tomycin. HEK-293 cells were cultured in DMEM high glucose 
media supplemented with 10% FBS (Gemini Biosciences, Den-
ver CO), 1% Sodium Pyruvate, and 1% Penicillin/Streptomycin. 




MTT assay of WI-38 and HEK 293 treated with NO releasing 
PDMS-WI-38 and HEK239 cells were treated with a range of 
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PDMS disks that release different NO fluxes (Table 1). Cells 
were incubated in treatment for 24 hours. MTT dye (5 mg/mL) 
was added directly to media for an incubation period of two and 
half hours at 37oC. Immediately after incubation, media was 
aspirated and replaced with MTT solubilization buffer (0.04 M 
HCl in isopropanol). Cells were shaken at room temperature in 
solubilization buffer for at least ten minutes and then absorbance 
at a wavelength of 570 nm was detected using biotech micro-
plate reader. Lower absorbance correlated to decreasing cell vi-
ability and viability was quantified as percent of control (absor-
bance from untreated cells).
Statistical Analysis 
Data are expressed as mean ± SD (standard deviation of the 
mean). Comparison of results were analyzed by a comparison of 
means using Student’s t-test or one way ANOVA. Values of p < 
0.05 were considered statistically significant for all tests.
RESULTS AND DISCUSSION
Prepared samples and their nitric oxide release
        
Bulk composition of modified PDMS with stimulated NO re-
lease illustration (left) and representative samples for biological 
testing (right) are shown in Scheme 2. Control PDMS samples 
unmodified with any additives, top, were transparent while NO 





 and PLGA. The samples measured 6.35 
mm ID and 1 mm in thickness.
Nitric oxide release from modified PDMS
          
To conveniently deliver different levels of NO to P. aeruginosa, 
WI-38 human lung fibroblasts, and HEK-293 human embry-
onic kidney cell, 15wt% DMHD/N2O2 +15wt% 5050DLG1A 
were stored at room temperature for various times before using 
them to treat bacteria and cells. The levels of NO released from 
PDMS as measured by chemiluminescence in terms of flux and 
total moles, and projected NO released into culture medium per 





) and polylactideglycolide, (left) and formulated samples showing 






minute is shown in (Table 1). All three levels of NO flux listed 
have been investigated on S. aureus and S. epidermidis strains in 
our previous study so in this work NO flux levels including the 
minimum effective flux were tested on P. aeruginosa and cells.
Effect of nitric oxide on bacteria and cells
The effect of 21.18 ± 5.31 × 10−10 mol/ min/ cm2 flux of NO 
on P. aeruginosa is shown in (Figure 1). It can be seen in the 
left panel that qualitatively, there were no differences in colony 
growths between control (untreated bacterial culture streaks) and 
PDMS (PDMS-treated culture streaks) groups. Significantly less 
colonies were observed in the NO releasing PDMS group where 
the colonies were sparsely spotted on the plates. Colony counts 
in the NO releasing PDMS group (54 ± 7) × 2×104 CFU/mL was 
significantly different from count in no-treatment control (607 
± 52) × 2×104 CFU/mL and PDMS-treated control (602 ± 28) 
× 2×104 CFU/mL groups, p < 0.001. The response of bacteria 
growth to NO release at (45.1 ± 2.546 × 10−10 mol/ min/ cm2), 
Figure 2, shows a significantly (p< 0.001) lower colony counts 
of 80 ± 69 × 2×105 CFU/mL compared to 625 ± 75 × 2×105 
CFU/mL and 700 ± 71 × 2×105 CFU/mL in the untreated control 
and PDMS-treated control groups respectively. Approximately 1 
log/ 90% reduction in colony counts was observed at either level 
of NO flux while a higher reduction was seen in the Levofloxa-
cin antibiotic positive control group, although at a level, (9 ± 2) 
× 2×105 CFU/mL, not significantly different compared to NO 
groups (p > 0.05).
Viabilities of WI-38 and HEK 293 cells responded differently 
to treatment with NO at various fluxes. At the low NO flux le-
vel of 0.48 ± 0.10 × 10−10 mol/ min/ cm2, the morphologies 
of WI- 38 and HEK-293 cells show no qualitative differences 
between their control and NO treatment groups. See (Figure 
3). The adherent and spreading behavior of WI-38 controls can 
also be seen in the treatment group and the quantitative analy-
sis of their viability showed no significant differences between 
controls [untreated cells and PDMS-treated cells (95 ± 10 %)] 
compared to the NO treatment group (117 ± 25%) (p > 0.05). 
The NO treatment group actually seem to improve in viability 
after the 24hr incubation period supporting the cell proliferative 
property of NO at low concentrations. In the HEK-293 cells, no 
observable difference in culture morphology was apparent, and 
no differences in viability was present between the controls and 
NO treatment groups (p > 0.05).
When the WI-38 cells were evaluated for their viability at 21.18 
± 5.31 × 10−10 mol/ min/ cm2, (Figure 4), again no statistically 
significant differences were observed among untreated control, 
PDMS-treated control (90 ± 12 %), and NO treatment groups 
(84 ± 15 %) (p > 0.05). Similarly, qualitative analysis of W1-38 
cell culture, the only cell line evaluated here, showed no dissi-
milar adherent and spreading behavior between controls and the 
NO treatment groups.
Finally, treatment of cells with the highest NO flux tested 
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PDMS Active Layer Composition Average NO flux (x 10-10 mol/min/cm2) Average total NO (moles)




45.10±2.55 1.60x1000 ± 0.89x10-01 1.16x10-03 ± 6.69x10-05
15wt% DMHD/N2O2 +15
wt%5050DLG1A (24hr cured + 24hr storage) 21.18±5.31 7.60 x10-01 ± 1.77 x10-01 5.47 x10-04± 1.28 x10-04
5wt% DMHD/N2O2 +15wt%
5050DLG1A (24hr cured + 48hr storage)
0.48±0.10 1.84 x10-02± 3.64 x10-03 1.29x10-05± 2.58 x10-06
Table 1: Averages of nitric oxide fluxes and averages of total nitric oxide moles released from NO releasing PDMS substrates used for in vitro testing on bacterial cells growth
Figure 2: The effect of NO flux (45.1 ± 2.546 × 10−10 mol/ min/ cm2) on P. aeruginosa growth in nutrient broth. Representative images of 1:100 dilution streaks of P. aeruginosa after 24 
hours of NO treatment (left) and colony counts (right) showing significant reduction in bacteria growth in the NO releasing group (***p < 0.001)
Figure 1: Antibacterial effect of 21.18 ± 5.31 × 10−10 mol/ min/ cm2 NO flux. Representative images of 1:10 dilution streaks of P. aeruginosa after 24 hours of NO treatment in comparison 
to control and PDMS alone (left). Quantitative analysis of streak plates, (n=12 per group), of P. aeruginosa shows significant reduction in colony count after NO treatment. Three asterisk 
denotes statistical significance (P value < 0.001)
Figure 3: The effect of low NO flux on cell viability. (A) Representative images of both cell lines with NO treatment. (B) NO flux at 0.48 ± 0.10 × 10−10 mol/ min/ cm2 promotes the 
growth in WI-38 cells.
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Figure 4: The effect of bactericidal NO flux on WI-38 human lung fibroblasts viability. No significant difference was found between groups. It shows no significant difference between 
control and cells treated with average NO flux of 21.18 ± 5.31 × 10−10 mol/ min/ cm2, average total NO moles delivered over 24 hours was 0.76 ± 0.177 mole.
Figure 5A: The Effect of high NO dosage on cell viability. Representative images of HEK-293 cells with NO treatment in comparison to controls. (5B) Significant reduction in cell viability 
after treatment with higher dose of nitric oxide (45.1 ± 2.546 x × 10−10 mol/ min/ cm2). For WI-38 cells (p value =0.0023) and for HEK-239 (p value =0.0027).
(45.10±2.55 × 10−10 mol/ min/ cm2), a level which showed 
the highest reduction in P. aeruginosa growth although not si-
gnificantly different from the 21.18 ± 5.31 × 10−10 mol/ min/ 
cm2 flux effect, affected viabilities as anticipated. It can be seen 
in Figure 5A that compared to untreated control WI-38 culture, 
cell viabilities after PDMS control and NO treatments were 94 
± 13% (p > 0.05) and 45 ± 07% (p < 0.05) respectively. With 
HEK-293 cells, viabilities were 100 ± 21% (p > 0.05) in PDMS 
control and 45 ± 18% (p < 0.05) in NO treatment compared to 
untreated controls. The morphology of HEK-293 cells elected 
for qualitative analysis of the effect of NO treatment revealed 
non- spreading and non-adherent properties. This was unlike the 
cell adhesion phenomenon seen in untreated and PDMS treated 
controls. The image in (Figure 5B) suggests the effect of such 
high level of NO flux can impair the spreading and adhesion 
of cells onto surfaces. Perhaps such levels significantly interact 
with cell adhesion molecules (CAMs) on cell membranes which 
are involved in cell adhesion, and may interfere with important 
CAMs properties such as maintaining tissue structure, function, 
and cell growth.
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CONCLUSION
This study investigated the cytocompatibility of antibacterial 
property of nitric oxide at different concentrations to determine 
effective antibacterial level of NO that could also be safe to he-
althy cells. PDMS biomaterials formulated to release different 
levels of NO was characterized for their total levels of relea-
sed NO, effect on gram positive (not included in this study) and 
gram negative bacteria growth as well as for an effective mini-
mum flux with antibacterial yet cytocompatible properties. The 
effects of the NO fluxes, including the effective minimum, on 
lung and kidney cells viabilities were also determined. The re-
sults from this work suggest that marginal antibacterial benefits 
are gained at fluxes greater than 21.18 ± 5.31 × 10−10 mol/ min/ 
cm2 and most importantly, cell viabilities at this NO level are 
seemingly not affected. The largest NO flux tested, 45.10±2.55 
× 10−10 mol/ min/ cm2, however had a negative effect on the 
viabilities of both cell lines.
Further studies including long term antibacterial NO effects on 
cytocompatibility using additional standard intracellular mar-
kers to evaluate cell function and the antibacterial functionali-
zation of implantable devices associated with risk of infection 
are needed to fully understand NO effects and to ensure safe and 
effective applications.
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